Ultrapar Participações S A : Clarifications on Preemptive Right Trading (UGPA1)

ULTRAPAR PARTICIPAÇÕES S.A.

MARKET ANNOUNCEMENT

Clarifications on Preemptive Right Trading (UGPA1)

São Paulo, June 30, 2021 - Ultrapar Participações S.A. (B3: UGPA3 / NYSE: UGP, "Ultrapar" or the "Company"), in complement to the material notice of May 18, 2021, the Management's proposal referring to the Extraordinary General Meeting of June 25, 2021 and the notice to shareholders issued on June 28, 2021, states that the Preemptive Right to acquire Extrafarma shares is available as of today and may be traded on the stock exchange under the ticker "UGPA1."

As previously clarified by the Company, the Preemptive Right is not related to Ultrapar shares, but to the shares of Extrafarma. Therefore, holders and purchasers of the Preemptive Right on the stock exchange will, upon exercising this right, be entitled to the conditioned right to acquire shares issued by Extrafarma, a privately-heldcompany that does not have shares traded on a securities market (a stock exchange or on an over-the-countermarket). Therefore, Extrafarma's shares do not have and there is no indication that they will have liquidity.

If you have any questions, please contact the Company's Investor Relations Department by e- mail at [e-mail] or by telephone at [phone].

Rodrigo de Almeida Pizzinatto

Chief Financial and Investor Relations Officer

Ultrapar Participações S.A.

This document shall not be considered an offer for the sale or request for the purchase of the marketable securities held by the Company or Extrafarma, as well as the marketable securities held by the Company or Extrafarma shall not be sold in any jurisdiction where such offer, request or sale is deemed unlawful.

The preemptive right in relation to the shares issued by Extrafarma was not, and shall not be registered in the context of the Securities Act of 1933, as amended ("Securities Act") or any other federal or state law of the United States, and such marketable securities may not be offered, sold, pledged or otherwise transferred in the United States or to other persons resident or domiciled in the United States or established in accordance with the laws of the United States (U.S. persons), except if such offer or sale is exempt or is not subject to registry in the context of the Securities Act and any applicable securities law enacted by the states of the United States.